Chris Cargill, Sosei Heptares CEO
August 2, 2022 07:07 AM EDT
Deals
R&D

With some neu­ro tar­gets in mind, Ab­b­Vie gets So­sei's drug dis­cov­ery en­gine churn­ing again

Amber Tong

Ab­b­Vie has got more work for So­sei Hep­tares.

A year and a half af­ter break­ing off a lega­cy Al­ler­gan pact in­volv­ing a slate of So­sei …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times